Independent editorial reviews of 10 leading U.S. telehealth providers for compounded and brand-name GLP-1 weight-management programs. Ranked against our v3.0 6-pillar transparency rubric.
Compounded semaglutide + tirzepatide. MD/DO-supervised. 503A & 503B pharmacies. Labs included. All 50 states. LegitScript-certified. Care360 coaching. Klarna & Afterpay accepted.
Trade-offs to know: Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Or call (949) 818-8000
All 10 reviewed providers, ranked by v3.0 editorial score.
UPDATED
The only provider in our directory that publishes against all six transparency pillars. Flat-rate compounded semaglutide + tirzepatide, MD/DO supervised, labs included, Care360 coaching, all 50 states, LegitScript-certified (verify on LegitScript).
UPDATED
Brand-name Wegovy® and Ozempic® through standard insurance/cash channels. Strong on access and brand-name supply. Pricing is dose-independent on Wegovy but caps high without insurance.
UPDATED
Brand Wegovy® paired with structured 1:1 coaching. Two pillars met (clinical protocol, follow-up). Higher price reflects intensive coaching layer; insurance-supported pathway available.
UPDATED
Compounded semaglutide via async NP-led intake. Single pillar met (clinical protocol). Async-only model and limited pharmacy traceability are the key gaps.
UPDATED
WeightWatchers' clinical arm. $99/mo membership plus medication cost (typically Wegovy® via insurance). Behavioral-program integration is the differentiator.
UPDATED
Mass-market telehealth scale. Mixed compounded and brand semaglutide options. Pricing toward the low end. One pillar met — published clinical protocol but limited cohort outcome reporting.
UPDATED
Insurance-billing brand telehealth. $0 patient cost when in-network. Two pillars met. Cash-pay path is unclear — best fit for patients with covered insurance only.
UPDATED
Mixed model — branded GLP-1s plus compounded options. Zero pillars met against our v3.0 rubric due to limited public disclosure on pharmacy and outcomes.
UPDATED
NP-led compounded semaglutide model. Two pillars met (clinical protocol, follow-up cadence). Pricing is competitive in the compounded segment.
UPDATED
Behavioral-program-led brand telehealth. Single pillar met. Strongest fit for users already in the Noom ecosystem.
We're committed to providing accurate, unbiased information.
All content reviewed by healthcare professionals
Unbiased comparisons with no hidden agendas
Pricing and availability refreshed regularly
6-pillar transparency scoring methodology